#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 winsnews2025-11-24T20:51:46+00:00November 24th, 2025|Endpoints News|
J&J’s tau-targeting antibody fails Phase 2 Alzheimer’s studynews2025-11-24T16:22:48+00:00November 24th, 2025|Endpoints News|
Kelun’s TROP2 ADC plus Keytruda improves outcomes in first-line lung cancernews2025-11-24T15:59:45+00:00November 24th, 2025|Endpoints News|
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 winnews2025-11-24T12:13:03+00:00November 24th, 2025|Endpoints News|
Novo Nordisk’s semaglutide misses in closely-watched Alzheimer’s trialsnews2025-11-24T12:10:32+00:00November 24th, 2025|Endpoints News|
Top Makary aide Jain-Nagpal remains at the FDA after White House pushbacknews2025-11-21T20:25:04+00:00November 21st, 2025|Endpoints News|
Contineum’s J&J-partnered drug fails Phase 2 multiple sclerosis trialnews2025-11-21T15:19:47+00:00November 21st, 2025|Endpoints News|
Under RFK Jr., vaccine use has slid while suspicion risesnews2025-11-20T20:47:17+00:00November 20th, 2025|Endpoints News|
Dispatches from Jefferies: Why Alkermes wants Avadel, Light Chain’s hope for CD47, and morenews2025-11-20T16:33:02+00:00November 20th, 2025|Endpoints News|
Post-Hoc Live: The drug industry’s Mr. Reality Check, Derek Lowenews2025-11-20T12:00:14+00:00November 20th, 2025|Endpoints News|
